When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ABBV - Galderma announces positive data on twice-yearly frown line treatment
AbbVie Inc.
Privately held Galderma announces the results from a 120-subject study, DREAM, assessing the safety and patient satisfaction of Dysport (abobotulinumtoxinA) for the temporary treatment of moderate-to-severe glabellar lines (frown lines) between the eyebrows in adults less than 65 years old.
More news on: AbbVie Inc., Revance Therapeutics, Inc., Evolus, Inc., Healthcare stocks news, Consumer stocks news,